These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10030499)

  • 1. FDA to require pediatric studies for drugs commonly used in children.
    Miller JL
    Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

  • 3. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
    Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA drug approval process: focus on pediatric labeling.
    Brummel GL
    Neonatal Netw; 2001 Apr; 20(3):49-51. PubMed ID: 12144214
    [No Abstract]   [Full Text] [Related]  

  • 7. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 8. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Regulation of Prescription Drugs.
    Gassman AL; Nguyen CP; Joffe HV
    N Engl J Med; 2017 Feb; 376(7):674-682. PubMed ID: 28199811
    [No Abstract]   [Full Text] [Related]  

  • 11. A much-anticipated FDA reform bill is signed into law: progress and compromise.
    Nissen SE
    Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 14. Botanical medicines--the need for new regulations.
    Marcus DM; Grollman AP
    N Engl J Med; 2002 Dec; 347(25):2073-6. PubMed ID: 12490692
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label prescribing and the standard of care.
    Johnson LJ
    Med Econ; 2001 Aug; 78(16):97. PubMed ID: 11550443
    [No Abstract]   [Full Text] [Related]  

  • 16. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA approves once-daily efavirenz formulation, revised labeling.
    AIDS Treat News; 2002 Mar; (378):7. PubMed ID: 11965921
    [No Abstract]   [Full Text] [Related]  

  • 18. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 20. Off-label prescribing. Legal implications.
    Henry V
    J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.